CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- 4 Grant or award President and CEO acquired 44,000 shares (grant or award)
- 4 Grant or award Director acquired 1,900 shares (grant or award)
- 4 Grant or award Senior VP, Finance & CAO acquired 9,600 shares (grant or award)
- 4 Open-market sale President and CEO sold 2,120 shares at $6.25 ($13,252)
- 4 Open-market sale EVP, Gen. Counsel, Corp. Sec. sold 847 shares at $6.25 ($5,298)
- 4 Open-market sale VP, Finance & Corp Controller sold 231 shares at $6.27 ($1,448)
- 4/A Insider Changes in Ownership
- 4/A Insider Changes in Ownership
- 4/A Insider Changes in Ownership
- 4 Grant or award EVP, Gen. Counsel, Corp. Sec. acquired 7,875 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award VP, Finance & Corp Controller acquired 2,875 shares (grant or award)
- 4 Grant or award President and CEO acquired 19,750 shares (grant or award)
- 4 Grant or award EVP, Gen. Counsel, Corp. Sec. acquired 35,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 4 of 22 · 436 filings